Holen Sie sich die Stockscreener-App
7.74
3.13%
-0.25
Handel nachbörslich:
7.77
0.03
+0.39%
Schlusskurs vom Vortag:
$7.99
Offen:
$7.98
24-Stunden-Volumen:
276.97K
Relative Volume:
0.79
Marktkapitalisierung:
$182.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.07M
KGV:
-37.27
EPS:
-0.2077
Netto-Cashflow:
$-44.93M
1W Leistung:
-3.61%
1M Leistung:
-5.03%
6M Leistung:
-20.78%
1J Leistung:
-29.01%
1-Tages-Spanne:
$7.74
$7.985
1-Wochen-Bereich:
$7.55
$8.18
52-Wochen-Spanne:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Firmenname
Cybin Inc
Sektor
Branche
Telefon
908 764 8385
Adresse
100 King Street West, Suite 5600, Toronto
Vergleichen Sie CYBN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.74 | 184.03M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Cybin Inc. Schedules Virtual Annual General Meeting for August 2025 - TipRanks
What are Cybin Inc. company’s key revenue driversFree Stock Chart Pattern Guide - jammulinksnews.com
What are analysts’ price targets for Cybin Inc. in the next 12 monthsInvest confidently with real-time data analysis - jammulinksnews.com
Why is Cybin Inc. stock attracting strong analyst attentionMaximize your portfolio’s growth potential - jammulinksnews.com
When is Cybin Inc. stock expected to show significant growthPre Market Trend Scanner With High Returns - jammulinksnews.com
Is Cybin Inc. stock overvalued or undervaluedConsistently superior profits - jammulinksnews.com
What institutional investors are buying Cybin Inc. stockAchieve consistent returns with proven methods - jammulinksnews.com
What are the technical indicators suggesting about Cybin Inc.Access high-yield investment alerts now - jammulinksnews.com
What is the dividend policy of Cybin Inc. stockInvest smarter with daily market updates - jammulinksnews.com
Should I hold or sell Cybin Inc. stock in 2025Extraordinary performance - jammulinksnews.com
How Cybin Inc. stock performs during market volatilitySolid Return Trade Selections - metal.it
What analysts say about Cybin Inc. stockSuperior portfolio returns - PrintWeekIndia
Cybin Inc. Stock Analysis and ForecastFree Capital Efficiency Planning - PrintWeekIndia
Is Cybin Inc. a good long term investmentExceptional growth trajectory - PrintWeekIndia
Cybin, Inc: CYB003 Vs. GH001Duration, Durability and Protocol Execution - Smartkarma
What drives Cybin Inc. stock pricePowerful market insights - PrintWeekIndia
Will Cybin Inc. stock benefit from AI tech trendsFree Predictions - jammulinksnews.com
I can have 5% loss. - AInvest
(CYBN) Proactive Strategies - news.stocktradersdaily.com
High-Risk, High-Reward Stocks With Serious Momentum: 5 Stocks to Consider - AInvest
Cybin Inc: CYB003 Phase 3 Program Continues to Progress on Plan - Smartkarma
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - Yahoo Finance
UK MHRA approves Cybin’s trial of CYB003 for major depressive disorder - Yahoo Finance
Three High-Risk, High-Reward Stocks in AI, Biotech, and Autonomous Vehicles - AInvest
Cybin's EMBRACE Study: A Pivotal Step in Psychedelic-Driven Mental Healthcare Innovation - AInvest
Cybin receives UK MHRA approval to commence EMBRACE study - TipRanks
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Cybin Secures UK Approval for Pivotal Depression Study - TipRanks
Cybin receives UK approval for second pivotal depression study By Investing.com - Investing.com South Africa
Cybin receives UK approval for second pivotal depression study - Investing.com Australia
Finanzdaten der Cybin Inc-Aktie (CYBN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
1.06%
Kapitalisierung:
|
Volumen (24h):